Kornimate/medical-research-clean huggingface dataset:
effect of myofascial release on dysphagia in patients with traumatic brain injury

Conditions: Traumatic Brain Injury

Summary: the goal of this clinical trial is to explore clinical effect of myofascial release therapy in dysphagic traumatic brain injured survivors. the main question it aims to answer is: • can myofascial release therapy improve swallowing function in traumatic brain injured survivors? patients will be randomly allocated into the control group or the experimental group, all under rehabilitation treatment, the experimental group will be given myofascial release therapy. the study lasts 21 days for each patient. researchers will compare the functional oral intake scale, penetration-aspiration scale, swallowing quality of life to see if the myofascial release therapy can help improve the situation.

myofascial release, also known as fascial release or fascial manipulation, is a physical therapy used to treat muscle and fascial tissue tension or pain. it involves applying appropriate pressure and stretching to release tight fascia and soft tissues, improving blood circulation, alleviating pain, and promoting rehabilitation. the goal of this clinical trial is to explore clinical effect of myofascial release therapy in dysphagic traumatic brain injured survivors. the main question it aims to answer is: • can myofascial release therapy improve swallowing function in traumatic brain injured survivors? patients will be randomly allocated into the control group or the experimental group, all under rehabilitation treatment, the experimental group will be given myofascial release therapy. the study lasts 21 days for each patient. researchers will compare the functional oral intake scale, penetration-aspiration scale, swallowing quality of life to see if the myofascial release therapy can help improve the situation.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years, meeting the diagnosis of severe traumatic brain injury. * presence of no contraindication for enteral nutrition; * with stable vital signs and no severe liver or kidney dysfunction, metabolic disorders, cardiovascular diseases, or multiple complications; exclusion criteria: * complicated with other neurological diseases; * damaged mucosa or incomplete structure in nasopharynx; * tracheostomy tube plugged; * unfeasible to myofascial release; * simultaneously suffering from liver, kidney failure, tumors, or hematological diseases.
reversal of neuromuscular blockade in diabetic patients

Conditions: Observation of Neuromuscular Block

Summary: in this study the investigators aimed to compare the time of antagonism and intensity of effect of sugammadex which is used for antagonism of rocuronium on diabetic and non-diabetic patients.

aim: in this study the investigators aimed to compare the time of antagonism and intensity of effect of sugammadex which is used for antagonism of rocuronium on diabetic and non-diabetic patients. methods: included patients were divided into 2 groups: diabetic (n=21) and non-diabetic (n=20). all patients were premedicated. after arrival in the operating room, all patients were monitorised with datex ohmeda s/5 anesthesia machine and electrocardiography (dii derivation), hemodynamic variables, respiratory rate, and inspiratory sevoflurane concentrations were recorded. neuromuscular monitoring system was used. anesthesia was induced with propofol 2 mg/kg and fentanyl 1 mcg/kg. after the loss of eyelid reflex the neuromuscular monitoring system automatically identified supramaximal stimulating currents and after that rocuronium 0,6 mg/kg was given. train of four (tof) stimulation with the supramaximal current were applied and by recording of second tof value (tof2) the patient was intubated. anesthesia was maintained with 50% o2 + 50% air and sevoflurane of 1-2 % concentration. tof stimulation was applied and recorded every 20 seconds. intraoperatively by return t2 rocuronium 0,15 mg/kg was given. t2i time was recorded as intubation time and t2d time was recorded as clinical effect time. at the end of the operation sugammadex 2 mg/kg was given. when tof rate reached 0,9 patients were extubated and the time was recorded.

Eligibility criteria:
inclusion criteria: * the patients (diabetic and non-diabetic) between 18-65 years with risk of anesthesia i-ii, * for diabetic group patients with diabetes mellitus type 2 over 10 years. * for non-diabetic group patients without any glucose metabolism disease exclusion criteria: * myasthenia gravis, myotonic dystrophia, motor neuron diseases * diabetic neuropathy and nephropathy * hepatic, renal and cardiac diseases

Keywords: diabetes mellitus neuromuscular blockade sugammadex
response to neoadjuvant chemoimmunotherapy in resectable locally advanced oral cancer

Conditions: Oral Cancer

Summary: the goal of this observational study is to investigate the effectiveness of neoadjuvant chemoimmunotherapy (naci) regimens in treating advanced oral squamous cell carcinoma (oscc) patients. we analyzed clinicopathologic features of advanced oscc patients who received pd-1 inhibitors in combination with carboplatin and paclitaxel before surgical tumor resection between 2020 and 2022. the response evaluation criteria in solid tumors (recist, version 1.1) and pathologic response were used to evaluate the efficacy of the naci treatment. adverse events apparently related to naci treatment were graded according to the common terminology criteria for adverse events, version 4.0. disease-free survival (dfs) and overall survival (os) were calculated using the kaplan-meier survival curves and compared using the log rank test. additionally, we calculated the area under curve (auc) to compare the predictive value of pd-l1 expression with baseline serum lipid biomarkers for patient response.


Eligibility criteria:
inclusion criteria: patients with advanced oscc who received naci before surgery * confirmation of primary oscc by two experienced pathologists; * clinical stage iii/ iva (ct1-2/cn1-2/m0 or ct3-4a/cn0-2/m0) according to the 8th edition of american joint committee on cancer (ajcc) guideline; * an eastern cooperative oncology group (ecog) performance status of 0 to 1; * no prior anti-cancer therapy; * locally resectable advanced tumor evaluated by a head and neck surgeon. advanced oscc patients who only received surgery * a histopathologic diagnosis of primary oscc; * a clinical stage of iii/iva (ajcc, 8th edition); * an ecog performance status of 0 to 1. exclusion criteria: patients with advanced oscc who received naci before surgery * patients with other pathological types, without naci or surgery; * incomplete pre-treatment data; * lost to follow up were excluded from the study. advanced oscc patients who only received surgery * patients who had received other therapies targeting the head and neck region before the surgery or those with evidence of recurrence or metastasis, as assessed by physical examination reports or imaging studies before surgery * lost to follow up.

Keywords: neoadjuvant chemoimmunotherapy, advanced oral squamous cell carcinoma, therapeutic response, predictive marker, prognosis
non alcoholic fatty liver disease: nutritional epidemiology and lifestyle medicine

Conditions: Non Alcoholic Fatty Liver Disease; Lifestyle; Diet Modification

Summary: the study is an open-label intervention non pharmacological cohort study without control arm in patients with non alcoholic fatty liver disease (nafld) and in healthy subjects. the intervention in patients with nafld is educational, providing personalized suggestions to improve diet and physical activity; the intervention in healthy subjects is educational, providing general suggestions to improve diet and physical activity.


Eligibility criteria:
inclusion criteria: * presence of fatty liver at ultrasonography exclusion criteria: * pregnancy; * breast feeding * cirrhosis or end stage liver disease * fatty liver due to hepatic diseases other than non alcoholic fatty liver disease * concomitant severe clinical condition
safety and immunogenicity of a surface antigen, inactivated, adjuvanted with mf59c.1, seasonal influenza vaccine, formulation 2009-2010

Conditions: Seasonal Influenza

Summary: this is a trial for annual registration of the updated seasonal influenza vaccine formulation.


Eligibility criteria:
key inclusion criteria: * subjects of 65 years of age or older * mentally competent * willing and able to give written informed consent prior to study entry * able to comply with all the study requirements * in general good health key exclusion criteria: * any serious chronic or acute disease disease * history of any anaphylactic reaction and/or serious allergic reaction following a vaccination * a proven hypersensitivity to any component of the study vaccine * known or suspected (or have a high risk of developing) impairment/alteration of immune function (excluding that normally associated with advanced age) * bleeding diathesis or conditions associated with prolonged bleeding time that in the investigator's opinion would interfere with the safety of the subject * within the past 12 months, participants had received more than one injection of influenza vaccine * within the past 6 months, participants had laboratory confirmed influenza disease or received influenza vaccine

Keywords: influenza vaccine
ghrelin and beta cell function in diabetes

Conditions: Type 2 Diabetes Mellitus

Summary: ghrelin is a hormone naturally produced in the stomach and the gut. the purpose of this research study is to determine the role of this gut hormone in the regulation of insulin secretion from the pancreas and glucose disposal after we eat. the investigators hypothesize that ghrelin has an effect on the pancreas and on how our body handles glucose after we eat. the investigators will compare insulin secretion and glucose changes during meal ingestion while either acyl ghrelin (ag) or saline (salt solution) is being infused through your vein on separate study days. ag is a form of the ghrelin hormone that has a small modification to it that allows it to bind to a specific receptor. the investigators hypothesize that ag has an effect on how the body handles glucose after a meal. ag has been approved by the u.s. food and drug administration (fda) for human research only. this study will also involve the use of a medicine called arginine, which is a naturally occurring product and found in many nutritional supplements. its use in this study is investigational. the use of arginine helps maximize insulin release from the pancreas so the investigators can better examine whether ag affects insulin secretion.


Eligibility criteria:
inclusion criteria: t2dm study subjects to be considered for the study must meet the following inclusion criteria: 1. established t2dm with good to moderate glycemic control 2. hba1c \< 8.5% 3. diabetes treatment with metformin, sulfonylurea, thiazolidinediones or combination of these medications; with no use of insulin during the study period 4. bmi ≤ 45.0 kg/m2 control study subjects will be matched for age- (± 2 years), bmi (± 1.5 kg/m2) and gender and must meet the following inclusion criteria: 1. hba1c ≤ 5.7% 2. fasting plasma glucose ≤ 95 mg/dl 3. bmi ≤ 45.0 kg/m2 exclusion criteria: all subjects will be excluded for the following reasons: 1. history of myocardial infarction or arrhythmia within the past year, abnormal electrocardiogram (ecg) with evidence of ischemia or arrhythmia, history or symptoms of congestive heart failure 2. uncontrolled hypertension 3. history or active liver or renal disease (ast or alt \>2x upper limits of normal, calculated glomerular filtration rate \[egfr\] \<60 at screening) 4. history of pituitary or adrenal disorders or neuroendocrine tumor 5. anemia defined as hematocrit \<33% at screening 6. active cancer diagnosis or currently undergoing cancer treatment 7. history of anorexia nervosa or previous gastrointestinal tract surgery 8. pregnancy or lactation control subjects will be excluded for the following reasons: 1. history or clinical evidence of impaired fasting glucose or impaired glucose tolerance on a 75 g ogtt, established diabetes mellitus, or taking medications prescribed for diabetes 2. use of medications that alter insulin sensitivity (i.e. niacin, glucocorticoids, metformin)

Keywords: ghrelin age, bmi, and gender matched controls
icu norepinephrine load

Conditions: Circulatory Collapse and Shock

Summary: norepinephrine is recommended as first-line vasopressor in critically ill patients, regardless of shock etiology. its advantages over dopamine and/or epinephrine have been demonstrated, especially by reducing tachycardia events. the current guidelines recommend a mean arterial pressure of at least 65 mmhg that in the resuscitation from sepsis-induced hypoperfusion. some study reported that delay in initiation of vasopressor therapy was associated with an increase mortality risk in patient with septic shock .the recent experts' opinion suggest that " vasopressors should be started early, before (complete) completion of fluid ressuscitation ". in the event of refractory septic shock, high-dose vasopressors may be used. the precise maximal dose of norepinephrine associated with mortality excess has been poorly studied. high doses have been defined by a cutoff value ranging from 0.5 μg/kg/min to 2 μg/kg/min and recently by 1 μg/kg/min for mortality at 90% and by 0,75 μg/kg/min for mortality at 60%. furthermore, an increasing vasopressor dosing intensity during the first 24 hours after shock septic was associated with increased mortality depending of fluid administration. if a threshold value of norepinephrine score can be obtained, it could indicate the association with another vasopressor such as vasopressin or surrogates. the primary aim of the present study aimed to confirm if a given norepinephrine dose is associated with mortality. the secondary aims were the link between mortality and norepinephrine duration, cumulative dose in order to build a score that predicts a futility of increasing norepinephrine dose.


Eligibility criteria:
inclusion criteria: * age \> 18 years * circulatory shock and admitted in icu * with norepinephrine exclusion criteria : patient without norepinephrine or missing data.

Keywords: norepinephrine load dose vasopressor dose intensity vasopressor exposure
a study of napabucasin (bbi-608) plus weekly paclitaxel versus weekly paclitaxel alone in patients with advanced, previously treated, non-squamous non-small cell lung cancer

Conditions: Carcinoma, Non-Small-Cell Lung

Summary: this is an international, multi-center, prospective, randomized, open-label phase 3 clinical trial of the cancer stemness inhibitor napabucasin administered with weekly paclitaxel versus weekly paclitaxel alone in patients with advanced non-squamous non-small cell lung cancer who have disease progression following systemic treatment with a platinum-based combination regimen in the metastatic setting, who have received treatment with an immune checkpoint inhibitor if a candidate, additional approved therapies, and for whom weekly paclitaxel is an acceptable treatment option.


Eligibility criteria:
key inclusion criteria: * must have histologically or cytologically confirmed non-squamous nsclc. * must have progressed following treatment with platinum-based combination chemotherapy for metastatic disease, and patients with an egfr or alk/ros1 genetic aberration must have received appropriately targeted treatment. * must have received either nivolumab or pembrolizumab or a different ind-approved anti-pd1 or anti-pd-l1 therapy, unless medically contraindicated * weekly paclitaxel must be an acceptable treatment option * must submit tumor tissue for correlative analyses * women of child-bearing potential and partners of women of child-bearing potential must take measures to avoid pregnancy while receiving and for a period of time following protocol therapy * must have an eastern cooperative oncology group (ecog) performance status of 0 or 1, adequate organ function, and a life expectancy of ≥ 3 months key exclusion criteria: * has squamous nsclc * has received prior systemic treatment with a taxane for advanced/metastatic disease * has received systemic anti-cancer therapy within the 14 days prior to randomization * has received radiotherapy within the 28 days prior to randomization, with the exception of palliative radiotherapy to focal lesions for pain or other symptom control * has brain metastases with evolving neurologic symptoms or a steroid requirement. * has had major surgery requiring general anesthesia and/or mechanical ventilation within the 28 days prior to randomization * has a corrected qt interval (qtc) \> 470 ms or has an electrocardiogram (ecg) with a new abnormal finding that is clinically significant * has peripheral neuropathy ≥ grade 2 (nci-ctcae) * refuses to complete quality of life questionnaires either alone or with assistance from study staff despite adequate fluency * has an intercurrent (non-malignant) chronic medical or psychiatric illness or condition(s) not optimally controlled and carrying a moderate to high risk of interfering with protocol therapy administration or compliance with required procedures, in the judgment of the investigator

Keywords: neoplasms neoplasms by site lung neoplasms thoracic neoplasms respiratory tract neoplasms bronchial neoplasms
study of ibi3005 in subjects with unresectable, locally advanced or metastatic solid tumors

Conditions: Unresectable; Locally Advanced or Metastatic Solid Tumors

Summary: the main purpose of this study is to evaluate the safety and tolerability of ibi3005 and to determine the maximum tolerated dose (mtd) and the recommended phase 2 dose (rp2d) of ibi3005.


Eligibility criteria:
inclusion criteria: subjects should have been previously treated with a third-generation egfr tki with disease progression. subjects with positive other driver genes or metex14 mutations are required to undergo targeted therapy and disease progression. exclusion criteria: received live vaccines within 4 weeks prior to first administration of the study drug or plan on receiving any live vaccine during the study.patients are allowed to receive inactivated vaccines. uncontrolled diseases including: * infection requiring systemic antibiotics, antivirals or antifungals within 2 weeks prior to first dose of the study drug（ antiviral medication for hepatitis b and hepatitis c infection that are compliant with the protocol were allowed）; * known human immunodeficiency virus (hiv) infection, or hiv positive (hiv 1/2 ab positive); * acute or chronic active hepatitis b (hbsag positive and/or hbcab positive with hbv dna titer ≥ 104 copies/ml or ≥ 2000 iu/ml or higher than lower limit of detection) or c (hcv ab positive with hcv rna titer \> 103 copies/ml or higher than lower limit of detection); * active covid-19 infection with obvious symptoms requiring treatment or hospitalization, such as pyrexia, dyspnea, nausea, vomiting, diarrhea, etc.; * active tuberculosis infection, or still on anti-tuberculosis therapy or received anti tuberculosis therapy within 1 year prior to first administration of the study drug; * active syphilis infection or latent syphilis requiring treatment; * symptomatic congestive heart failure grade ii-iv (new york heart association \[nyha\]), symptomatic or uncontrolled arrhythmias, qtc interval \> 480 ms or personal or family history of congenital long/short qt syndrome; * hypertension that does not receive standardized therapy or still uncontrollable hypertension (sbp ≥ 160 mmhg or dbp ≥ 100 mmhg); any history of life-threatening hemorrhage, or hemorrhage requiring (including but not limited to gastrointestinal bleeding, hemoptysis, etc) blood transfusion, endoscopy, or surgery, within 3 months prior to the first administration of study drug;
effectiveness of digital cognitive behavioral therapy for the treatment of depression

Conditions: Depression

Summary: the project proposes to develop a digital product based on cognitive behavioral therapy for the assisted treatment of depression. the digital cognitive behavioral therapy in this study is conducted based on a self-developed mobile applet. the therapy is developed by psychotherapists, which is conducted for a total of 8 weeks, with weekly sessions including ai-guided course work and homework. the aim of this study is to evaluate the therapeutic effect of a digital product based on cognitive behavioral therapy for the assisted treatment of depression in patients through a randomised controlled trial, and to explore its genetic imaging mechanisms.


Eligibility criteria:
inclusion criteria: 1. aged 18-45 years (including 18 and 45), no gender restriction; 2. meets the diagnostic criteria for depressive disorders according to the diagnostic and statistical manual of mental disorders, fifth edition (dsm-iv); 3. outpatients or inpatients; hamilton depression rating scale 17-item (hamd-17) score ≥ 17; clinical global impressions-severity (cgi-s) score = 4; 4. maintenance treatment with antidepressants in the class of selective serotonin reuptake inhibitors (ssris) for at least 4 weeks, or no previous treatment with antidepressants, and can be combined with lorazepam 0.5mg/dose and zolpidem tartrate 5-10mg/n during insomnia and anxiety attacks; 5. written informed consent obtained from the patient. exclusion criteria: 1. diagnosed with other mental disorders, including schizophrenia, bipolar disorder, alcohol or substance abuse/dependence, eating disorders, etc.; 2. individuals with intellectual disabilities or who are unable to cooperate for other reasons, or those lacking or having incomplete civil capacity during the onset of illness; 3. suffering from neurological or organic brain diseases (such as stroke, cerebral hemorrhage, brain tumors, parkinson's disease, epilepsy, etc.) and a history of severe traumatic brain injury; 4. currently undergoing systematic psychological therapy; 5. individuals who had been treated with convulsion-free electroconvulsive therapy within the last month; 6. pregnant women or individuals with contraindications to mri examinations; 7. individuals who don't know how to use or don't have a smartphone; 10. individuals with severe suicidal tendencies or at risk of harming others.

Keywords: i-cbt
frequency of metabolic syndrome in down syndrome patients

Conditions: Metabolic Syndrome X; Down Syndrome

Summary: the aim of this study is to assess the frequency of metabolic syndrome in down syndrome patients because the prevalence of diabetes mellitus and obesity is higher in individuals with down syndrome than in the general population.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of down syndrome exclusion criteria: * history of congenital cardiac defects requiring open-heart surgery * history of gastroenterologic anomalies requiring bowel resection and/or ongoing medical intervention * history of leukemia or other cancer * history of hypothyroidism requiring thyroid hormone replacement

Keywords: down syndrome metabolic syndrome x insulin resistance
2-year mortality after covid-19 in nursing home residents

Conditions: Covid19

Summary: this was a retrospective study conducted in three nursing homes (nhs). residents who had survived the 1st copw (march to may 2020) were included. the diagnosis of covid-19 was based on the results of a positive reverse transcriptase-polymerase chain reaction test. the collected data also included age, sex, length of residence in the nh, disability status, legal guardianship status, nutritional status, need for texture-modified food, hospitalization or emergency department visits during lockdown and sars-cov2 vaccination status during the follow-up. non-adjusted and adjusted cox models were used to analyse factors associated with 2-year post-1stcopw mortality.


Eligibility criteria:
inclusion criteria: * living in one of the nursing homes during the fiorst covid-19 pandemic wave * having survived the first pandemic wave exclusion criteria: * residents who died during the first pandemic wave * refusal for articipation to the study

Keywords: covid-19 older adults nursing home long-tem mortality